º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Second stay of execution for Novartis as production plans extended in Grimsby

Extension until end of 2022 announced to more than 200 remaining staff

Building 150 at Novartis Grimsby. (Image: Novartis)

Grimsby’s Novartis plant is to remain open for a further year, after a second stay of execution was confirmed.

More than 200 jobs have been safeguarded until the end of 2022, with plans for the pharmaceutical giant to leave put on hold again.

A bombshell announcement in September 2018 originally scheduled the South Humber Bank site to close at the end of 2020.

That was put back 12 months for the majority of staff last May when one of three drug-producing units, Building 110, was closed, with the remainder - Buildings 120 and 150 - extended to the end of 2021.

A further 12 months have now been added, with staff told today, Tuesday, June 8, providing a significant short-term boost to the economy.

Ian Johnson, managing director, said: “We will extend the manufacturing of two products at Novartis Grimsby until quarter four 2022.

Ian Johnson, managing director of Novartis Grimsby Ltd.(Image: Novartis)

“We were due to exit the site at the end of 2020 as part of a global transformation to our manufacturing network.

Last May we announced some manufacturing would continue until the end of 2021, largely due to increasing demand for two products.